Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BeOne Medicines Ltd.ONC · Entity 2168 | Director · Chief Executive Officer | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BeOne Medicines Ltd.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2026-08-12 transaction · row 30
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
24 source rowsRow 7 · 2026-08-10 · Sale · Disposed 67 · Balance 240,743 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. Row 8 · 2026-08-10 · Sale · Disposed 2,813 · Balance 237,930 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.01 to $351.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 9 · 2026-08-10 · Sale · Disposed 3,673 · Balance 234,257 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.00 to $353.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 10 · 2026-08-10 · Sale · Disposed 6,717 · Balance 227,540 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.03 to $355.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 11 · 2026-08-10 · Sale · Disposed 3,476 · Balance 224,064 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.08 to $356.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 12 · 2026-08-10 · Sale · Disposed 12,418 · Balance 211,646 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.08 to $357.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 13 · 2026-08-10 · Sale · Disposed 15,869 · Balance 195,777 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.08 to $358.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 14 · 2026-08-10 · Sale · Disposed 45,044 · Balance 150,733 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.08 to $359.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 15 · 2026-08-10 · Sale · Disposed 21,254 · Balance 129,479 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.08 to $360.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 16 · 2026-08-10 · Sale · Disposed 3,680 · Balance 125,799 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.25 to $361.14, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 17 · 2026-08-11 · Sale · Disposed 13,695 · Balance 112,104 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.90 to $359.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 18 · 2026-08-11 · Sale · Disposed 8,081 · Balance 104,023 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.92 to $360.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 19 · 2026-08-11 · Sale · Disposed 14,569 · Balance 89,454 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.92 to $361.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 20 · 2026-08-11 · Sale · Disposed 11,568 · Balance 77,886 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.94 to $362.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 21 · 2026-08-11 · Sale · Disposed 13,403 · Balance 64,483 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.95 to $363.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 22 · 2026-08-11 · Sale · Disposed 5,211 · Balance 59,272 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.95 to $364.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 23 · 2026-08-11 · Sale · Disposed 3,176 · Balance 56,096 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 24 · 2026-08-11 · Sale · Disposed 1,200 · Balance 54,896 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 25 · 2026-08-11 · Sale · Disposed 4 · Balance 54,892 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. Row 26 · 2026-08-12 · Sale · Disposed 1,980 · Balance 52,912 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.35 to $355.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 27 · 2026-08-12 · Sale · Disposed 2,515 · Balance 50,397 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.92 to $356.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 28 · 2026-08-12 · Sale · Disposed 15,396 · Balance 35,001 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F27: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.95 to $357.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 29 · 2026-08-12 · Sale · Disposed 20,899 · Balance 14,102 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F28: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.95 to $358.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. Row 30 · 2026-08-12 · Sale · Disposed 14,102 · Balance 0 F6: Each American Depositary Share represents 13 Ordinary Shares. F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026. F29: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.95 to $359.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,330,988 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,330,988 |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 481,533 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 481,533 F1: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 7,699,158 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,699,158 F2: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 28,204,115 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 28,204,115 F3: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 9,545,000 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 9,545,000 F4: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account. |
| Ordinary SharesSEC Table I · non-derivative | IndirectSee Footnote | 102,188 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 102,188 F5: These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.
F2: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F3: These securities are held by Oyler Investment LLC, of which 99% of the limited liability company interests are owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
F4: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
F5: These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's child, for which the Reporting Person disclaims beneficial ownership.
F6: Each American Depositary Share represents 13 Ordinary Shares.
F7: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2026.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.01 to $351.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.00 to $353.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.03 to $355.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.08 to $356.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F12: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.08 to $357.06, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F13: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.08 to $358.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F14: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.08 to $359.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F15: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.08 to $360.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F16: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.25 to $361.14, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F17: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.90 to $359.89, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F18: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.92 to $360.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F19: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.92 to $361.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F20: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.94 to $362.74, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F21: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.95 to $363.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F22: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.95 to $364.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F23: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.00 to $365.90, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F24: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.00 to $366.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F25: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.35 to $355.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F26: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.92 to $356.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F27: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.95 to $357.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F28: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.95 to $358.94, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
F29: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.95 to $359.68, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2020 Filed Jul 22, 2020 22:14 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,211 | $249.82 | $552,344.50 |
DisclosureSEC source: 0001651308-20-000104 · wf-form4_159545605043345.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,851 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $249.08 to $250.07, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 22:14 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 700 | $248.70 | $174,088.18 |
DisclosureSEC source: 0001651308-20-000104 · wf-form4_159545605043345.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,062 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $248.02 to $248.96, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 08, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,854 | $203.81 | $581,680.30 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 20 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F21 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.47 to $204.28, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 08, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,834 | $202.37 | $775,895.01 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 19 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,854 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.00 to $202.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 08, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,841 | $201.58 | $975,868.63 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 18 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,688 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.00 to $201.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 08, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,900 | $200.55 | $581,597.03 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 17 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,529 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.00 to $200.96, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 08, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,800 | $199.26 | $358,672.32 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 16 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,429 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.81 to $199.80, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 08, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 700 | $197.98 | $138,584.60 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 15 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,229 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.65 to $198.22, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 08, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 600 | $196.51 | $117,907.98 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 14 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,929 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.41 to $196.72, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 8,318 | $199.88 | $1,662,566.90 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 13 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.44 to $200.30, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 5,474 | $199.01 | $1,089,391.14 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,318 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.43 to $199.42, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,501 | $197.80 | $296,903.20 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 11 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,792 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.43 to $198.41, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 07, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,730 | $196.82 | $734,125.92 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,293 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.27 to $197.24, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,561 | $198.32 | $507,901.11 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.10 to $198.59, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 6,300 | $197.43 | $1,243,810.26 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,561 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $197.03 to $198.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,701 | $196.62 | $1,514,203.73 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,861 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.03 to $197.01, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 06, 2020 Filed Jul 8, 2020 21:20 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 800 | $195.43 | $156,347.04 |
DisclosureSEC source: 0001651308-20-000093 · wf-form4_159424322252549.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,562 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.02 to $195.73, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 01, 2020 Filed Jul 1, 2020 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,800 | $192.08 | $345,751.56 |
DisclosureSEC source: 0001651308-20-000089 · wf-form4_159363616189353.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F9 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2017, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.00 to $192.255, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| July 01, 2020 Filed Jul 1, 2020 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,016 | $191.10 | $385,264.66 |
DisclosureSEC source: 0001651308-20-000089 · wf-form4_159363616189353.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F9 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 30, 2017, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.00 to $191.41, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 35 | $193.68 | $6,778.80 |
DisclosureSEC source: 0001651308-20-000089 · wf-form4_159363616189353.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,100 | $192.84 | $212,127.63 |
DisclosureSEC source: 0001651308-20-000089 · wf-form4_159363616189353.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.50 to $193.47, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 20:43 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 300 | $191.56 | $57,468.00 |
DisclosureSEC source: 0001651308-20-000089 · wf-form4_159363616189353.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,135 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 26, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $191.34 to $192.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,725 | $189.42 | $326,745.02 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 19 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F20 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.87 to $189.71, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,800 | $188.20 | $715,162.66 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 18 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,725 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F19 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.87 to $188.83, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,115 | $187.10 | $769,914.03 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 17 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,525 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F18 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.61 to $187.48, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,741 | $186.11 | $882,334.24 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 16 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,640 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F17 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.57 to $186.52, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 410 | $188.43 | $77,257.98 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 15 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,381 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F16 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.42 to $188.50, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,438 | $187.46 | $1,394,334.92 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 14 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,791 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $187.10 to $188.08, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 4,922 | $186.63 | $918,568.74 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 13 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,229 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.09 to $187.08, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,610 | $185.54 | $298,711.99 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,151 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.08 to $186.03, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 690 | $184.56 | $127,348.40 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 11 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,761 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $184.01 to $185.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,095 | $183.72 | $568,600.71 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,451 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.37 to $184.11, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 3,714 | $182.78 | $678,838.98 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,546 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.31 to $183.21, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,772 | $181.79 | $322,138.26 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,260 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.31 to $182.26, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 800 | $180.50 | $144,400.96 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,032 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.06 to $180.71, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 22, 2020 Filed Jun 25, 2020 00:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 900 | $179.58 | $161,626.23 |
DisclosureSEC source: 0001651308-20-000086 · wf-form4_159304457821189.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,832 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.02 to $179.91, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:06 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | GrantShare Option (Right to Buy) · Derivative | 1,821,976 | $0.00 Strike: $13.42 | $0.00 |
DisclosureSEC source: 0001651308-20-000073 · wf-form4_159259715257694.xml · derivative · entry 1 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,821,976 Underlying: Ordinary Shares · 1,821,976 shares Expires 2030-06-16 F1 · derivative.exercise_price: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F2 · derivative.exercise_date: These securities vest over a four-year period as follows: 25% on the first anniversary of June 17, 2020 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested shares are subject to accelerated vesting upon change of control or certain termination events. F1 · derivative.underlying_shares: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. F1 · balance_after: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each American Depositary Share represents 13 ordinary shares. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:14 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 900 | $175.07 | $157,563.00 |
DisclosureSEC source: 0001651308-20-000068 · wf-form4_159199284323253.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.00 to $175.22, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 474 | $141.00 | $66,834.00 |
DisclosureSEC source: 0001651308-20-000046 · wf-form4_158871168978852.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person on April 30, 2018. 1/4th of the securities will vest on each anniversary of April 30, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,859 | $140.96 | $403,004.64 |
DisclosureSEC source: 0001651308-20-000046 · wf-form4_158871168978852.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 474 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person on April 30, 2018. 1/4th of the securities will vest on each anniversary of April 30, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 302 | $143.17 | $43,237.13 |
DisclosureSEC source: 0001651308-20-000046 · wf-form4_158871168978852.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person on April 30, 2018. 1/4th of the securities will vest on each anniversary of April 30, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.00 to $143.56, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:48 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,000 | $142.46 | $142,461.60 |
DisclosureSEC source: 0001651308-20-000046 · wf-form4_158871168978852.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,635 F5 · security: Each American Depositary Share represents 13 Ordinary Shares. F6 · kind: The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person on April 30, 2018. 1/4th of the securities will vest on each anniversary of April 30, 2018, subject to continued service. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.00 to $142.99, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares sold at each separate price. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 1,958 | $165.61 | $324,262.81 |
DisclosureSEC source: 0001651308-19-000136 · wf-form4_157678981368580.xml · nonDerivative · entry 12 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.35 to 165.86, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 200 | $163.20 | $32,640.00 |
DisclosureSEC source: 0001651308-19-000136 · wf-form4_157678981368580.xml · nonDerivative · entry 11 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,958 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 2,400 | $162.42 | $389,796.48 |
DisclosureSEC source: 0001651308-19-000136 · wf-form4_157678981368580.xml · nonDerivative · entry 10 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,158 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.095 to $162.85, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 18,215 | $161.49 | $2,941,527.60 |
DisclosureSEC source: 0001651308-19-000136 · wf-form4_157678981368580.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,558 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.06 to $162.055, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 16,965 | $160.60 | $2,724,572.21 |
DisclosureSEC source: 0001651308-19-000136 · wf-form4_157678981368580.xml · nonDerivative · entry 8 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,773 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.06 to $161.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares, sold at each separate price. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 15,466 | $159.59 | $2,468,195.74 |
DisclosureSEC source: 0001651308-19-000136 · wf-form4_157678981368580.xml · nonDerivative · entry 7 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,738 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.06 to $160.05, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 21:10 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 7,055 | $158.63 | $1,119,105.02 |
DisclosureSEC source: 0001651308-19-000136 · wf-form4_157678981368580.xml · nonDerivative · entry 6 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,204 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2019. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.06 to $159.02, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depository Shares, sold at each separate price. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 23:23 UTC | BeOne Medicines Ltd. BGNE · Entity 2168 | SaleAmerican Depositary Shares | 100 | $128.80 | $12,880.00 |
DisclosureSEC source: 0001651308-19-000073 · wf-form4_156271462402442.xml · nonDerivative · entry 9 OYLER JOHN · CIK 0001042047 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · security: Each American Depositary Share represents 13 Ordinary Shares F6 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax withholdings in connection with the vesting of restricted share unit awards previously granted to the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.